AI-Designed pill enters human testing for tough blood cancers
NCT ID NCT06980116
Summary
This is the first human study of an experimental oral drug called EXS73565 for people with advanced B-cell blood cancers that have returned or stopped responding to standard treatments. The main goal is to find a safe dose and understand how the drug behaves in the body, while also looking for early signs that it might help control the cancer. The study will enroll about 50 adults who have run out of standard treatment options.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY B-CELL MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hospital Fundación Jiménez Diaz
RECRUITINGMadrid, Spain
-
Hospital Universitario HM Sanchinarro
RECRUITINGMadrid, Spain
-
St James's University Hospital
RECRUITINGLeeds, United Kingdom
-
University Hospitals Plymouth NHS Trust
RECRUITINGPlymouth, United Kingdom
Conditions
Explore the condition pages connected to this study.